← Leaderboards
Maryam B. Lustberg
Ohio State University
$3,432,763
Attributed
$7,582,196
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $916.5K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,582,196 · 5
By mechanism
R01$6,874,980 · 3
R21$553,341 · 1
R03$153,875 · 1
Top collaborators
- Lise C. Worthen-Chaudhari6 shared
- Shuiying Hu5 shared
- Anne Courtney Devries4 shared
- Tonya S Orchard4 shared
- Ajit Mohan Worthen Chaudhari2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Shuiying Hu$2,114,418
- Lise C. Worthen-Chaudhari$1,164,383
- David P Carbone$20,647,321
- Jennifer A. Woyach$6,733,332
- Carolyn Presley$1,438,820
Others in their field
Top investigators on “Quality Of Life”
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Gregory H Reaman · National Childhood Cancer Foundation$264,644,476
- David R. Weir · University Of Michigan At Ann Arbor$263,050,576
- Richard K. Wilson · Washington University$198,912,538
Research focus
Quality Of LifeChemotherapySymptomsAffectMalignant Breast NeoplasmIncidencePreventionNeuropathyFutureRandomizedReportingSensoryDoseMotorPreventToxic EffectDose-LimitingPharmaceutical PreparationsCancer SurvivorBreast Cancer SurvivorMouse ModelNeurologicBaseChemotherapy Induced Neuropathy
Grant awards (17)
Dance-based Avenues to Advance Nonpharmacologic treatment of Chemotherapy Effects (DAANCE): a multicenter trial$858,969
R01 · FY2025 · AG
Dance-based Avenues to Advance Nonpharmacologic treatment of Chemotherapy Effects (DAANCE): a multicenter trial$916,455
R01 · FY2024 · AG
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$569,420
R01 · FY2023 · CA
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$569,418
R01 · FY2022 · CA
Novel Interventions for Chemotherapy-Induced Neuropathy$203,312
R21 · FY2022 · AG
Novel Interventions for Chemotherapy-Induced Neuropathy$81,709
R21 · FY2022 · AG
Novel interventions for chemotherapy-induced neuropathy$38,772
R21 · FY2022 · AG
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$584,565
R01 · FY2021 · CA
Novel Interventions for Chemotherapy-Induced Neuropathy$229,548
R21 · FY2021 · AG
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$602,095
R01 · FY2020 · CA · contact PI
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$624,048
R01 · FY2019 · CA · contact PI
Effect of n-3 fatty acids and sugars on chemotherapy-induced cognitive deficits$438,106
R01 · FY2018 · CA
Effect of n-3 fatty acids and sugars on chemotherapy-induced cognitive deficits$581,756
R01 · FY2017 · CA
Effect of n-3 fatty acids and sugars on chemotherapy-induced cognitive deficits$559,544
R01 · FY2016 · CA
Effect of n-3 fatty acids and sugars on chemotherapy-induced cognitive deficits$570,604
R01 · FY2015 · CA
Gait and Balance Changes in Chemotherapy Induced Peripheral Neuropathy$77,000
R03 · FY2015 · CA · contact PI
Gait and Balance Changes in Chemotherapy Induced Peripheral Neuropathy$76,875
R03 · FY2014 · CA · contact PI